We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs
EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs
October 9, 2012
Drugmakers evaluating multiple sclerosis (MS) treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft EMA guideline.